F-1/A: Baird Medical Reports Q2 Loss Amid Revenue Decline, Share Dilution Risk

Baird Medical Investment Holdings Limited reported a significant net loss and revenue decline in the first half of 2025, while facing substantial potential share dilution from selling securityholders and out-of-the-money warrants.

Summary

• Baird Medical Investment Holdings Limited, a Cayman Islands holding company operating primarily in China, specializes in microwave ablation medical devices for tumor treatment.
• The company reported a net loss of US$11.4 million for the six months ended June 30, 2025, a significant decline from a net income of US$4.4 million in the same period of 2024.
• Total revenues decreased by 38.9% to US$8.0 million in the first half of 2025, down from US$13.1 million in the first half of 2024, primarily due to decreased sales of MWA needles.
• Operating expenses increased substantially, with research and development expenses rising from US$2.0 million to US$7.2 million, and general and administrative expenses increasing from US$3.2 million to US$8.7 million, largely due to increased share-based compensation and R&D expenditures.
• Accounts receivable turnover days dramatically increased from 337 days in 2023 to 1,077 days in the first half of 2025, indicating significant challenges in collecting customer payments.
• The company's Ordinary Shares and Warrants are listed on Nasdaq under symbols BDMD and BDMD W, respectively, with the Ordinary Share closing price at US$1.63 and Warrants at US$0.06 on December 4, 2025.
• Up to 34,415,562 Ordinary Shares, representing approximately 70.9% of issued and outstanding shares, are registered for potential resale by Selling Securityholders, which could cause significant market price volatility.
• The company will not receive proceeds from the sale of shares by Selling Securityholders; proceeds from warrant exercises (up to US$132,250,000) are unlikely given the current market price of US$1.63 is below the US$11.50 exercise price.
• Baird Medical completed a business combination with ExcelFin Acquisition Corp. on October 1, 2024, through a reverse recapitalization.

Sentiment

Score: 2

Explanation: The company's financial performance has significantly deteriorated, reporting a net loss and substantial revenue decline in H1 2025. Worsening accounts receivable collection days indicate severe liquidity issues. While there are strong R&D efforts and market positioning in China, the immediate financial results, high dilution risk from selling shareholders, and unlikely warrant exercise proceeds present significant headwinds and financial instability.

Positives

• The company is a leading microwave ablation medical device developer and provider in the PRC, ranking first for thyroid nodules and breast lumps in 2022 by sales revenue and volume.
• First company to have proprietary microwave ablation medical devices specifically approved for thyroid nodules registered as Class III medical devices in the PRC.
• Extensive sales and distribution network across 24 provinces in China, serving 614 hospitals (329 Grade III hospitals) in H1 2025.
• Strong R&D capabilities, with 54 registered patents and 28 pending applications in China, and collaborations with academic institutions and hospitals.
• FDA 510(k) clearance obtained on November 13, 2023, for disposable microwave ablation needle and system for coagulation (ablation) of soft tissue (excluding cardiac use) in the U.S. market.
• Management team has deep industry knowledge and experience, with the CEO having over 20 years in medical devices.
• The company has a product pipeline targeting breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids, with clinical trials underway or planned.

Negatives

• Reported a net loss of US$11.4 million for the six months ended June 30, 2025, compared to a net income of US$4.4 million in the prior year period.
• Total revenues decreased by 38.9% to US$8.0 million in the first half of 2025.
• Accounts receivable turnover days increased significantly to 1,077 days in H1 2025, indicating severe collection challenges and liquidity strain.
• Warrants are significantly out-of-the-money (exercise price US$11.50 vs. market price US$1.63), making cash exercise unlikely and limiting potential capital inflow from warrant exercises.
• Selling Securityholders may sell up to 34,415,562 Ordinary Shares (70.9% of outstanding shares), potentially causing significant market price decline and volatility.
• Certain Selling Securityholders may still profit from sales due to acquiring shares at prices substantially below current market prices, creating an incentive to sell despite low public trading prices.
• Increased R&D expenses (US$7.2 million in H1 2025) and general and administrative expenses (US$8.7 million in H1 2025) contributed to the net loss.
• The transaction with Wu Wenyuan for US$2 million in Series A Preferred Shares has not consummated, and an updated timeline is not available.

Risks

• Limited operating history makes future growth and financial performance difficult to predict.
• Historical high gross profit margin may not be sustainable due to market changes, regulatory environment, competition, and increasing costs.
• Inability to obtain, maintain, or renew regulatory filings and registration certificates for medical devices in a timely manner, or at all, particularly for Class III devices.
• Failure to maintain or renew permits, licenses, and certificates required for business operations, as evidenced by a past administrative penalty for a lapsed manufacture license.
• Inability to maintain or renew relationships with existing distributors and customers, or to maintain its sales network, especially given customer concentration.
• Sales may be adversely affected by changes in medical insurance reimbursement levels in China, including potential removal from reimbursement lists or price reductions.
• Failure to successfully complete product registration testing or clinical trials in a timely manner and at acceptable costs, or at all, for pipeline products.
• Inability to obtain Class III medical device registration certificates for additional diseases (e.g., breast lumps, pulmonary nodules, varicose veins, bone tumors, uterine fibroids) in a timely manner.
• Ineffective management of deliverers or distributors, leading to violations of agreements, sales guidelines, or laws, which could harm business and reputation.
• Inability to develop or successfully market new or commercially viable products and technologies in response to market changes, or if existing products become obsolete.
• Quality defects in products causing safety issues and exposing the company to potential product liability claims, especially without product liability insurance.
• Rapid deterioration in accounts receivable collection performance, straining liquidity and increasing exposure to credit defaults.
• Unsuccessful bids in public tender processes for marketing products to hospitals, limiting sales network expansion.
• Potential requirements from government authorities to contribute additional social insurance premiums or housing provident funds, or imposition of late payment fees or fines.
• Reliance on marketing service providers and industry participants, whose cooperation or market insights may be inaccurate or cease.
• Reliance on third-party suppliers for raw materials, with risks of disruption, inadequate quantities, quality issues, or price increases.
• Increasing dependence on information technology, with risks of service interruptions, security breaches, or cyber-attacks.
• Negative publicity and allegations involving the company, its stakeholders, or business partners affecting reputation and financial performance.
• Failure to successfully implement business strategies or achieve anticipated objectives.
• Adverse effects on business operations from relationships between China and other countries, including trade policies, tariffs, and political tensions.
• Conflicts of interest arising from transactions with related parties.
• Fines for failure to comply with PRC laws and regulations relating to safety facilities.
• Disruptions to manufacturing facilities due to natural disasters, epidemics, or other factors beyond control, or issues with leased properties.
• Inability to retain key management and personnel, or to attract and motivate qualified staff, leading to labor shortages or increased costs.
• Intense competition in the medical technology industry, potentially affecting market share and profitability.
• Inaccurate projection of demand for microwave ablation medical devices, leading to inadequate supply or oversupply.
• Increased difficulty and cost to obtain regulatory approval and commercialize products due to new and future legislation, including centralized procurement programs.
• Increased compliance costs and potential suspension/termination of future securities offerings due to additional disclosure requirements and regulatory scrutiny from the SEC regarding China-based operations.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
• Risk of being treated as a U.S. corporation or surrogate foreign corporation for U.S. federal income tax purposes under Section 7874 of the Code, leading to substantial tax liabilities.
• Uncertainties in the interpretation and enforcement of PRC laws, rules, and regulations, including those related to foreign investment, data security, and overseas listings.
• Restrictions on the ability of PRC subsidiaries to transfer cash or assets out of mainland China or Hong Kong due to governmental controls on currency conversion and dividend distributions.
• Potential delisting from Nasdaq under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect auditors located in China for two consecutive years.
• Difficulties for U.S. regulators to investigate and collect evidence from companies located in the PRC, limiting shareholder protection through U.S. courts.
• Volatility in the price of securities due to various factors, including financial performance, regulatory changes, and sales by selling securityholders.
• Risks associated with going public via a SPAC business combination, which may involve less careful vetting and lower investor demand compared to a traditional IPO.
• Dilution to shareholders from the exercise of warrants and future issuance of additional share capital.
• Exclusive forum provisions in the warrant agreement potentially limiting warrant holders' ability to choose a favorable judicial forum.
• Warrants may expire worthless if the Ordinary Share price remains below the exercise price.
• Ability to redeem unexpired public warrants at a disadvantageous time for holders, making them worthless.
• Lack of intent to pay dividends before becoming profitable, meaning returns depend on share price appreciation.
• Significant portion of outstanding shares subject to lock-up arrangements, but their eventual release could cause price declines.
• Reduced reporting and disclosure requirements as an emerging growth company and foreign private issuer may make securities less attractive to investors.
• Increased costs and management time required for public company compliance.
• Risk of securities class action suits.

Future Outlook

The company plans to broaden and deepen its product portfolio through R&D collaborations, aiming to register Class III medical devices for breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids by 2026-2027. It intends to enhance R&D capabilities by investing approximately US$18.7 million through 2027 in microwave ablation intelligence, including AI robotic surgery assistance. The company also seeks to expand its presence in foreign markets (U.S., EU, Southeast Asia) by establishing overseas offices and collaborations, with FDA 510(k) clearance already obtained and CE mark status targeted for selected devices. Strategic acquisitions or investments in microwave ablation, laser ablation, and AI technologies are also being pursued. Automation of production lines is planned to increase efficiency and standardization.

Management Comments

• Management believes microwave ablation treatments are safer, less invasive, and easier to operate with faster recovery periods and lower complication rates for patients compared to traditional methods.
• Management believes that patients diagnosed with benign tumors are inclined to seek tumor removal to avoid the risks of cancer progression.
• Management believes that there are viable alternatives in the market that can meet demands and needs at comparable price points and quality for raw materials.
• Management believes that the offices and manufacturing plants currently leased are adequate to meet needs for the foreseeable future.
• Management believes that employees contribute to rapid business growth, and continued success depends on attracting, motivating, training, and retaining qualified employees.
• Management believes that existing insurance coverage is in line with industry norms in the PRC and is sufficient for current operations.
• Management believes that the encouragement of innovation across multiple systems under the 2021 Medical Device Regulations is conducive to the development of innovative medical devices.
• Management believes that the adjustment to the procedures for review, approval and filing are conducive to accelerating the registration and marketing of the relevant pipeline products, enhancing compliance, and creating an orderly development environment for companies.
• Management believes that the 2022 Supervisory and Administrative Measures for Production will not have a material impact on business operations.
• Management believes that commissioned production was legal and valid under relevant PRC laws and regulations.
• Management believes that the Commission Guidelines will not have any material and adverse impact on business operation.
• Management believes that the products sold through distributors in certain geographic regions have not violated the two-invoice system.
• Management believes that the Cayman Islands holding company is not a PRC resident enterprise for PRC tax purposes.

Industry Context

The company operates in the rapidly growing PRC microwave ablation market, which is the largest sector of China's tumor ablation therapy market, contributing 60% of the overall ablation market in 2021. The market size is projected to reach RMB12.26 billion by 2027, with microwave ablation procedures expected to reach 640,700 by 2027, driven by increasing cancer patients and adoption of minimally invasive operations. The U.S. and European microwave ablation markets are also projected to grow significantly, reaching US$151.5 million and US$110.2 million (thyroid cancer) / US$9.5 million (breast cancer) respectively by 2027. The PRC market is highly concentrated with four top manufacturers accounting for 88.4% of sales in 2022, where Baird Medical is the third largest with a 19.0% market share. The industry faces high barriers to entry due to R&D, long commercialization processes, and established branding/sales channels.

Comparison to Industry Standards

• The company ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022, according to the Frost & Sullivan Report.
• The company was the third largest microwave ablation medical device provider in the PRC in terms of sales revenue in 2022, with a market share of 19.0%, in a highly concentrated market where the top four manufacturers account for 88.4% of sales.
• The company is the first to have proprietary microwave ablation medical devices specifically approved for the treatment of thyroid nodules successfully registered as Class III medical devices in the PRC, differentiating it from competitors like ECO Medical, Vison Medical, and Canyon Medical.
• The company's microwave ablation treatments offer advantages over traditional methods (surgery, radiotherapy, chemotherapy) and other ablation techniques (radiofrequency, cryoablation, laser ablation) in terms of safety, invasiveness, recovery time, and complication rates, as well as preventing cancer progression.
• The company's products are included in medical insurance reimbursement lists in ten provinces in China, which is a favorable position in the Chinese healthcare system.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to, nor aware of, any legal proceeding, investigation, or claim likely to have a material adverse effect on its business, financial condition, or results of operations as of the filing date.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.

Related Party Transactions

• In 2023, Betters Medical and Haimei Wu (Chairwoman and CEO) repurchased Preference Shares from one Electing Preference Shares Holder for RMB10,000,000 and US$683,638.21 (Betters Medical) and US$499,994.24 (Haimei Wu).
• Grand Fortune Capital (H.K.) Company Limited, an affiliate of GFC, purchased 641,371 preference shares from an Electing Preference Shares Holder for US$8,712,178.41 on June 30, 2023.
• The repurchase request of a third Electing Preference Shares Holder for 174,825 Preference Shares (valued at RMB17.8 million as of September 30, 2023) remains outstanding.
• Haimei Wu is the legal owner of premises co-occupied by the Guangdong branch office of Baide Suzhou.
• The company's use of its Taicang Plant is under a sublease agreement with affiliated entities.
• The company is party to a Subscription Agreement dated June 30, 2021, and a Shareholders Agreement dated July 5, 2021, with certain affiliates and Haimei Wu.
• Sponsor Support Agreement: ExcelFin SPAC LLC agreed to vote in favor of the Business Combination, surrender 11,700,000 private placement warrants, convert working capital loans into Ordinary Shares, and not transfer founder shares for a lock-up period.
• Betters Medical Shareholder Support Agreement: Key Betters Medical Shareholders agreed to vote in favor of the Business Combination, not transfer Betters Medical shares (with exceptions), and waive dissenters' rights.
• Subscription Agreement with GFC: Baird Medical issued 290,000 Series A convertible preferred shares for US$2.9 million concurrently with the Business Combination closing.
• Subscription Agreement with Wu Wenyuan: Wu Wenyuan agreed to pay US$2 million for 200,000 Series A Preferred Shares, but this transaction has not consummated.
• Lock-Up Agreement: Betters Medical agreed not to transfer Ordinary Shares acquired in the Share Contribution for six months from the Closing Date, with earnout shares vesting based on price targets or change of control.
• Warrant Assignment, Assumption and Amendment Agreement: ExcelFin's public warrants were converted into Baird Medical warrants, and private placement warrants were cancelled.
• Registration Rights Agreement: Baird Medical agreed to file a shelf registration statement for the resale of Registrable Securities by Holders (including Sponsor and Betters Medical) and granted demand and piggyback registration rights.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the resale of 70.9% of outstanding shares by Selling Securityholders, and potential volatility in share price. Existing public shareholders may experience lower returns than Selling Securityholders who acquired shares at much lower prices. Warrants are out-of-the-money, making exercise unlikely and limiting potential value for warrant holders. U.S. Holders face complex U.S. federal income tax considerations, including potential PFIC status and Section 7874 rules.
• Employees: Subject to potential labor shortages or increased labor costs. The company's success depends on attracting and retaining qualified personnel. The 2024 Equity Incentive Plan aims to motivate and retain employees, consultants, and non-employee directors.
• Customers (Hospitals, Deliverers, Distributors): May experience reduced demand for products due to changes in medical insurance reimbursement policies. The company's ability to maintain relationships and high-quality products is crucial for customer retention. Deteriorating accounts receivable collection performance from customers could impact the company's ability to supply.
• Suppliers: The company's reliance on a few major suppliers for raw materials creates risk of disruption, quality issues, or price increases, potentially impacting product manufacturing.
• Creditors: The company's liquidity is strained by worsening accounts receivable collection and increased debt, which could affect its ability to meet commitments.
• Regulatory Authorities: The company is subject to extensive and evolving PRC and U.S. regulations, including those related to medical device registration, production, data security, foreign investment, and overseas listings. Non-compliance could lead to fines, penalties, or business disruptions.

Next Steps

• Complete ethics review and execute clinical research contracts for breast lump and pulmonary nodule clinical trials by December 2025.
• Begin enrolling participants for breast lump and pulmonary nodule clinical trials in December 2025.
• Complete research participant enrollment for breast lump and pulmonary nodule clinical trials by April 2026.
• Finish clinical trial data collection for breast lump and pulmonary nodule clinical trials by May 2026.
• Complete semi-final and finalized clinical trial research reports for breast lump and pulmonary nodule clinical trials by June 2026.
• Submit EU CE certification materials for thyroid nodules in December 2025, with expected certification by mid-2026.
• Submit clinical trial results for NMPA and CE certification for breast lumps and pulmonary nodules product lines, and CE certification for thyroid nodules product line around August 2026.
• Continue product registration testing for bone tumors and uterine fibroids, expected to be completed by June 2027.
• Conduct pre-clinical activities on microwave ablation intelligence in 2025 and complete relevant clinical trials in 2027.
• Expand and increase headcount of the research and development team.
• Expand presence in foreign and emerging markets (U.S., EU, Southeast Asia) by establishing overseas offices and seeking local collaborations.
• Automate certain production steps in manufacturing plants to increase operational efficiency and product standardization.
• Recruit qualified staff to assist with financial reporting requirements and internal control remediation.

Key Dates

Recommendation

The company's financial performance has severely deteriorated, reporting a net loss of US$11.4 million in H1 2025 compared to a net income in the prior year, alongside a significant revenue decline. The alarming increase in accounts receivable turnover days to 1,077 days signals critical liquidity and cash flow issues. Furthermore, the substantial overhang of 70.9% of outstanding shares registered for resale by Selling Securityholders, many of whom acquired shares at significantly lower prices, poses a severe dilution risk and is likely to exert downward pressure on the stock price. The warrants are deeply out-of-the-money, indicating no near-term capital infusion from exercises. While the company has R&D initiatives and a strong market position in China, the immediate financial instability, coupled with significant regulatory and operational risks associated with operating in China and being a foreign private issuer, makes the stock a high-risk investment with a negative outlook. Investors should consider selling to mitigate further losses.

Keywords

Microwave Ablation, Medical Devices, Thyroid Nodules, Liver Cancer, China Healthcare, SEC Filing, F-1/A, Nasdaq, BDMD, Biotechnology, Minimally Invasive Treatment, Tumor Ablation, Healthcare Innovation, AI Robotic Surgery, Clinical Trials, Regulatory Approval, PRC Regulations, HFCAA, SPAC, Reverse Recapitalization, Warrants, Share Dilution, Financial Performance, Accounts Receivable, R&D Expenses